All In MedTech

FDA Clearance Tracker · P130009-S037

SAPIEN XT TRANSCATHETER HEART VALVE AND ACCESSORIES

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Feb 29, 2016 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Feb 29, 2016

Approved

Time to decision

243 days

Received Jul 1, 2015. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

Class III

The decision

FDA number
P130009-S037
Device name
SAPIEN XT TRANSCATHETER HEART VALVE AND ACCESSORIES
Applicant location
Irvine, CA
Received
Jul 1, 2015
Decided
Feb 29, 2016
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P130009

Device type

Device class
Class III

Every decision under product code NPT

FDA's approval statement

As written in FDA's record.

Approval for use in pediatric and adult patients with a dysfunctional, non-compliant Right Ventricular Outflow Tract (RVOT) conduit with a clinical indication for intervention and: 1) pulmonary regurgitation >= moderate and/or; and 2) mean RVOT gradient >= 35 mmHg.

Source documents

Other decisions for Edwards Lifesciences, LLC

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.